Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-07

AUTHORS

Partha Sardar, Saurav Chatterjee, Debabrata Mukherjee

ABSTRACT

INTRODUCTION: Currently available anticoagulants have limitations for long term treatment of venous thromboembolism (VTE). OBJECTIVE: A meta-analysis was performed to evaluate the efficacy and safety of new oral anticoagulants (NOACs) for extended treatment of VTE. METHODS: PubMed, Cochrane Library, EMBASE, Web of Science and CINAHL databases were searched from January 01, 2001 through February 28, 2013. Randomized controlled trials (RCTs) comparing NOACs (apixaban, rivaroxaban and dabigatran) with placebo or warfarin for extended treatment of VTE were selected. Primary efficacy outcome was recurrent VTE or VTE related death, and primary safety outcome was major bleeding. We used random-effects models. RESULTS: Four RCTs included 7,877 participants. NOACs significantly lowered the risk of recurrent VTE or VTE-related death compared to placebo/warfarin (odds ratio [OR] 0.25, 95 % confidence interval [CI] 0.07 to 0.86; number needed to treat [NNT] = 30). All-cause mortality was significantly lower in NOACs group compared to placebo (OR 0.38, 95 % CI 0.18 to 0.80). Risk of major bleeding was not different with NOACs compared to placebo/warfarin (OR 0.88, 95 % CI 0.27 to 2.91). However, NOACs caused significantly higher rate of major or clinically relevant bleeding compared to placebo (OR 2.69, 95 % CI 1.25 to 5.77; number needed to harm [NNH] = 39). All three NOACs (apixaban, rivaroxaban and dabigatran) individually significantly reduced recurrent VTE or VTE-related death compared to placebo. Major or clinically relevant bleeding was higher with dabigatran and rivaroxaban but not with apixaban. CONCLUSION: NOACs are effective for the extended treatment of venous thromboembolism and may reduce the risk of all-cause mortality. Dabigatran and rivaroxaban may cause more major or clinically relevant bleeding. More... »

PAGES

1171-1182

References to SciGraph publications

  • 2008-02. Treatment of DVT: how long is enough and how do you predict recurrence in JOURNAL OF THROMBOSIS AND THROMBOLYSIS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s40265-013-0082-7

    DOI

    http://dx.doi.org/10.1007/s40265-013-0082-7

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1013999734

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/23812923


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Oral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anticoagulants", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Randomized Controlled Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Venous Thromboembolism", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Department of Medicine, New York Medical College-Metropolitan Hospital Center, 1901 First Avenue, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sardar", 
            "givenName": "Partha", 
            "id": "sg:person.01335370606.01", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335370606.01"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Brown University", 
              "id": "https://www.grid.ac/institutes/grid.40263.33", 
              "name": [
                "Brown University and The Providence VAMC, Providence, RI, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chatterjee", 
            "givenName": "Saurav", 
            "id": "sg:person.01335424066.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335424066.40"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Texas Tech University Health Sciences Center", 
              "id": "https://www.grid.ac/institutes/grid.449768.0", 
              "name": [
                "Texas Tech University Health Sciences Center, El Paso, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mukherjee", 
            "givenName": "Debabrata", 
            "id": "sg:person.01134263324.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134263324.09"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.3810/pgm.2010.03.2122", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002649115"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.jacc.2013.03.020", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008375134"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa035029", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021338426"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1538-7836.2012.04874.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025409354"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa1207541", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029448177"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199903253401201", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031615046"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa1113697", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031831401"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1136/bmj.e7498", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031837169"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199903253401209", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032604310"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa035422", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033456279"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa1114238", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040155001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejme1215678", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041318884"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11239-007-0103-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044003504", 
              "https://doi.org/10.1007/s11239-007-0103-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa1007903", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044711794"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.3324/haematol.10516", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046146730"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1378/chest.08-0658", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1067171732"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.7326/0003-4819-125-1-199607010-00001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1073700525"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.7326/0003-4819-151-4-200908180-00136", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1073710983"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2013-07", 
        "datePublishedReg": "2013-07-01", 
        "description": "INTRODUCTION: Currently available anticoagulants have limitations for long term treatment of venous thromboembolism (VTE).\nOBJECTIVE: A meta-analysis was performed to evaluate the efficacy and safety of new oral anticoagulants (NOACs) for extended treatment of VTE.\nMETHODS: PubMed, Cochrane Library, EMBASE, Web of Science and CINAHL databases were searched from January 01, 2001 through February 28, 2013. Randomized controlled trials (RCTs) comparing NOACs (apixaban, rivaroxaban and dabigatran) with placebo or warfarin for extended treatment of VTE were selected. Primary efficacy outcome was recurrent VTE or VTE related death, and primary safety outcome was major bleeding. We used random-effects models.\nRESULTS: Four RCTs included 7,877 participants. NOACs significantly lowered the risk of recurrent VTE or VTE-related death compared to placebo/warfarin (odds ratio [OR] 0.25, 95 % confidence interval [CI] 0.07 to 0.86; number needed to treat [NNT] = 30). All-cause mortality was significantly lower in NOACs group compared to placebo (OR 0.38, 95 % CI 0.18 to 0.80). Risk of major bleeding was not different with NOACs compared to placebo/warfarin (OR 0.88, 95 % CI 0.27 to 2.91). However, NOACs caused significantly higher rate of major or clinically relevant bleeding compared to placebo (OR 2.69, 95 % CI 1.25 to 5.77; number needed to harm [NNH] = 39). All three NOACs (apixaban, rivaroxaban and dabigatran) individually significantly reduced recurrent VTE or VTE-related death compared to placebo. Major or clinically relevant bleeding was higher with dabigatran and rivaroxaban but not with apixaban.\nCONCLUSION: NOACs are effective for the extended treatment of venous thromboembolism and may reduce the risk of all-cause mortality. Dabigatran and rivaroxaban may cause more major or clinically relevant bleeding.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s40265-013-0082-7", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1084788", 
            "issn": [
              "0012-6667", 
              "1179-1950"
            ], 
            "name": "Drugs", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "73"
          }
        ], 
        "name": "Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials", 
        "pagination": "1171-1182", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "42b0ee940daf2dade69dd4465fd045a6d3646b74c3588db3cc5b1015d4b434cf"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "23812923"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "7600076"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s40265-013-0082-7"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1013999734"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s40265-013-0082-7", 
          "https://app.dimensions.ai/details/publication/pub.1013999734"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T20:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000521.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs40265-013-0082-7"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40265-013-0082-7'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40265-013-0082-7'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40265-013-0082-7'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40265-013-0082-7'


     

    This table displays all metadata directly associated to this object as RDF triples.

    171 TRIPLES      21 PREDICATES      54 URIs      28 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s40265-013-0082-7 schema:about N3a682b3b6d8f4c07b60ae8ea81974f13
    2 N55880980ba5045fc83d80489cfe43d51
    3 N726c835863e04cb3a9b388ced5796672
    4 N8608efe8fa524ecdafdd7a7594ee9e86
    5 Nae921cb818914ac199b07a92a7341d43
    6 Nc401d367560d4077a8dbae870daf0026
    7 Ne5bb557ab8d84c4384d9a03f758faf2c
    8 anzsrc-for:11
    9 anzsrc-for:1103
    10 schema:author N3fde2a884f114c0f94c7445202b53788
    11 schema:citation sg:pub.10.1007/s11239-007-0103-z
    12 https://doi.org/10.1016/j.jacc.2013.03.020
    13 https://doi.org/10.1056/nejm199903253401201
    14 https://doi.org/10.1056/nejm199903253401209
    15 https://doi.org/10.1056/nejme1215678
    16 https://doi.org/10.1056/nejmoa035029
    17 https://doi.org/10.1056/nejmoa035422
    18 https://doi.org/10.1056/nejmoa1007903
    19 https://doi.org/10.1056/nejmoa1113697
    20 https://doi.org/10.1056/nejmoa1114238
    21 https://doi.org/10.1056/nejmoa1207541
    22 https://doi.org/10.1111/j.1538-7836.2012.04874.x
    23 https://doi.org/10.1136/bmj.e7498
    24 https://doi.org/10.1378/chest.08-0658
    25 https://doi.org/10.3324/haematol.10516
    26 https://doi.org/10.3810/pgm.2010.03.2122
    27 https://doi.org/10.7326/0003-4819-125-1-199607010-00001
    28 https://doi.org/10.7326/0003-4819-151-4-200908180-00136
    29 schema:datePublished 2013-07
    30 schema:datePublishedReg 2013-07-01
    31 schema:description INTRODUCTION: Currently available anticoagulants have limitations for long term treatment of venous thromboembolism (VTE). OBJECTIVE: A meta-analysis was performed to evaluate the efficacy and safety of new oral anticoagulants (NOACs) for extended treatment of VTE. METHODS: PubMed, Cochrane Library, EMBASE, Web of Science and CINAHL databases were searched from January 01, 2001 through February 28, 2013. Randomized controlled trials (RCTs) comparing NOACs (apixaban, rivaroxaban and dabigatran) with placebo or warfarin for extended treatment of VTE were selected. Primary efficacy outcome was recurrent VTE or VTE related death, and primary safety outcome was major bleeding. We used random-effects models. RESULTS: Four RCTs included 7,877 participants. NOACs significantly lowered the risk of recurrent VTE or VTE-related death compared to placebo/warfarin (odds ratio [OR] 0.25, 95 % confidence interval [CI] 0.07 to 0.86; number needed to treat [NNT] = 30). All-cause mortality was significantly lower in NOACs group compared to placebo (OR 0.38, 95 % CI 0.18 to 0.80). Risk of major bleeding was not different with NOACs compared to placebo/warfarin (OR 0.88, 95 % CI 0.27 to 2.91). However, NOACs caused significantly higher rate of major or clinically relevant bleeding compared to placebo (OR 2.69, 95 % CI 1.25 to 5.77; number needed to harm [NNH] = 39). All three NOACs (apixaban, rivaroxaban and dabigatran) individually significantly reduced recurrent VTE or VTE-related death compared to placebo. Major or clinically relevant bleeding was higher with dabigatran and rivaroxaban but not with apixaban. CONCLUSION: NOACs are effective for the extended treatment of venous thromboembolism and may reduce the risk of all-cause mortality. Dabigatran and rivaroxaban may cause more major or clinically relevant bleeding.
    32 schema:genre research_article
    33 schema:inLanguage en
    34 schema:isAccessibleForFree false
    35 schema:isPartOf Na888c41f32cb4b18a305d5fec2bc5efe
    36 Ne83ce59962c54c5993c5cf25adc5a2cf
    37 sg:journal.1084788
    38 schema:name Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials
    39 schema:pagination 1171-1182
    40 schema:productId N4061a50f0aca4f829a29adb68e2426a0
    41 N5ce9db46f07248ec86ffdc80eb9e54ec
    42 N67b7e92578fb4272a0bac6f757ce6f77
    43 N7ca19cd419b94ea486a5c4b5f0253ec5
    44 Ncde7302792254572a10d89ace77d9d2f
    45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013999734
    46 https://doi.org/10.1007/s40265-013-0082-7
    47 schema:sdDatePublished 2019-04-10T20:49
    48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    49 schema:sdPublisher N4dcf26c19619404890cc8846091c58ff
    50 schema:url http://link.springer.com/10.1007%2Fs40265-013-0082-7
    51 sgo:license sg:explorer/license/
    52 sgo:sdDataset articles
    53 rdf:type schema:ScholarlyArticle
    54 N067671b0da104f42b8e3bb046112d0c5 rdf:first sg:person.01134263324.09
    55 rdf:rest rdf:nil
    56 N3a682b3b6d8f4c07b60ae8ea81974f13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    57 schema:name Randomized Controlled Trials as Topic
    58 rdf:type schema:DefinedTerm
    59 N3fde2a884f114c0f94c7445202b53788 rdf:first sg:person.01335370606.01
    60 rdf:rest Nf165d8316ee94006a22663f15dd8cb87
    61 N4061a50f0aca4f829a29adb68e2426a0 schema:name dimensions_id
    62 schema:value pub.1013999734
    63 rdf:type schema:PropertyValue
    64 N4dcf26c19619404890cc8846091c58ff schema:name Springer Nature - SN SciGraph project
    65 rdf:type schema:Organization
    66 N55880980ba5045fc83d80489cfe43d51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    67 schema:name Anticoagulants
    68 rdf:type schema:DefinedTerm
    69 N5ce9db46f07248ec86ffdc80eb9e54ec schema:name readcube_id
    70 schema:value 42b0ee940daf2dade69dd4465fd045a6d3646b74c3588db3cc5b1015d4b434cf
    71 rdf:type schema:PropertyValue
    72 N67b7e92578fb4272a0bac6f757ce6f77 schema:name pubmed_id
    73 schema:value 23812923
    74 rdf:type schema:PropertyValue
    75 N726c835863e04cb3a9b388ced5796672 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    76 schema:name Time Factors
    77 rdf:type schema:DefinedTerm
    78 N7ca19cd419b94ea486a5c4b5f0253ec5 schema:name doi
    79 schema:value 10.1007/s40265-013-0082-7
    80 rdf:type schema:PropertyValue
    81 N8608efe8fa524ecdafdd7a7594ee9e86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    82 schema:name Humans
    83 rdf:type schema:DefinedTerm
    84 Na888c41f32cb4b18a305d5fec2bc5efe schema:issueNumber 11
    85 rdf:type schema:PublicationIssue
    86 Nae921cb818914ac199b07a92a7341d43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    87 schema:name Treatment Outcome
    88 rdf:type schema:DefinedTerm
    89 Nc401d367560d4077a8dbae870daf0026 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    90 schema:name Administration, Oral
    91 rdf:type schema:DefinedTerm
    92 Ncde7302792254572a10d89ace77d9d2f schema:name nlm_unique_id
    93 schema:value 7600076
    94 rdf:type schema:PropertyValue
    95 Nda26acc9bd654b25b9203d89ac47bce1 schema:name Department of Medicine, New York Medical College-Metropolitan Hospital Center, 1901 First Avenue, New York, NY, USA
    96 rdf:type schema:Organization
    97 Ne5bb557ab8d84c4384d9a03f758faf2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Venous Thromboembolism
    99 rdf:type schema:DefinedTerm
    100 Ne83ce59962c54c5993c5cf25adc5a2cf schema:volumeNumber 73
    101 rdf:type schema:PublicationVolume
    102 Nf165d8316ee94006a22663f15dd8cb87 rdf:first sg:person.01335424066.40
    103 rdf:rest N067671b0da104f42b8e3bb046112d0c5
    104 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    105 schema:name Medical and Health Sciences
    106 rdf:type schema:DefinedTerm
    107 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    108 schema:name Clinical Sciences
    109 rdf:type schema:DefinedTerm
    110 sg:journal.1084788 schema:issn 0012-6667
    111 1179-1950
    112 schema:name Drugs
    113 rdf:type schema:Periodical
    114 sg:person.01134263324.09 schema:affiliation https://www.grid.ac/institutes/grid.449768.0
    115 schema:familyName Mukherjee
    116 schema:givenName Debabrata
    117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134263324.09
    118 rdf:type schema:Person
    119 sg:person.01335370606.01 schema:affiliation Nda26acc9bd654b25b9203d89ac47bce1
    120 schema:familyName Sardar
    121 schema:givenName Partha
    122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335370606.01
    123 rdf:type schema:Person
    124 sg:person.01335424066.40 schema:affiliation https://www.grid.ac/institutes/grid.40263.33
    125 schema:familyName Chatterjee
    126 schema:givenName Saurav
    127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335424066.40
    128 rdf:type schema:Person
    129 sg:pub.10.1007/s11239-007-0103-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1044003504
    130 https://doi.org/10.1007/s11239-007-0103-z
    131 rdf:type schema:CreativeWork
    132 https://doi.org/10.1016/j.jacc.2013.03.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008375134
    133 rdf:type schema:CreativeWork
    134 https://doi.org/10.1056/nejm199903253401201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031615046
    135 rdf:type schema:CreativeWork
    136 https://doi.org/10.1056/nejm199903253401209 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032604310
    137 rdf:type schema:CreativeWork
    138 https://doi.org/10.1056/nejme1215678 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041318884
    139 rdf:type schema:CreativeWork
    140 https://doi.org/10.1056/nejmoa035029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021338426
    141 rdf:type schema:CreativeWork
    142 https://doi.org/10.1056/nejmoa035422 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033456279
    143 rdf:type schema:CreativeWork
    144 https://doi.org/10.1056/nejmoa1007903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044711794
    145 rdf:type schema:CreativeWork
    146 https://doi.org/10.1056/nejmoa1113697 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031831401
    147 rdf:type schema:CreativeWork
    148 https://doi.org/10.1056/nejmoa1114238 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040155001
    149 rdf:type schema:CreativeWork
    150 https://doi.org/10.1056/nejmoa1207541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029448177
    151 rdf:type schema:CreativeWork
    152 https://doi.org/10.1111/j.1538-7836.2012.04874.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025409354
    153 rdf:type schema:CreativeWork
    154 https://doi.org/10.1136/bmj.e7498 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031837169
    155 rdf:type schema:CreativeWork
    156 https://doi.org/10.1378/chest.08-0658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067171732
    157 rdf:type schema:CreativeWork
    158 https://doi.org/10.3324/haematol.10516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046146730
    159 rdf:type schema:CreativeWork
    160 https://doi.org/10.3810/pgm.2010.03.2122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002649115
    161 rdf:type schema:CreativeWork
    162 https://doi.org/10.7326/0003-4819-125-1-199607010-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073700525
    163 rdf:type schema:CreativeWork
    164 https://doi.org/10.7326/0003-4819-151-4-200908180-00136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073710983
    165 rdf:type schema:CreativeWork
    166 https://www.grid.ac/institutes/grid.40263.33 schema:alternateName Brown University
    167 schema:name Brown University and The Providence VAMC, Providence, RI, USA
    168 rdf:type schema:Organization
    169 https://www.grid.ac/institutes/grid.449768.0 schema:alternateName Texas Tech University Health Sciences Center
    170 schema:name Texas Tech University Health Sciences Center, El Paso, TX, USA
    171 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...